argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

argenx SE

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

VIRTRIS is a health data pioneer based in Seoul, South Korea, specializing in health data integration and analysis with the goal to accelerate drug discovery and approval.

VIRTRIS

argenx focuses on innovating immunology solutions to reach patients.

Metric
Company Name	argenx SE	LégiaPark	Therini Bio	VIRTRIS
Symbol	ARGX
MSH ID	COM:ARGENX	BE:LEGIAPARK	COM:THERINIBIO	COM:VIRTRIS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Life Sciences	Biotechnology	Biotechnology
Country	NL	BE	US	KR
Stage
Employee Count	1.15K
Website	argenx.com	legiapark.be	therinibio.com	virtris.com
LinkedIn		l%C3%A9giapark	therinibio	virtus
Founders

Metric
Market Cap	26.54B
Enterprise Value
Monthly Web Traffic	29.27K
Web Traffic Growth	0.59
Valuation
Raised Capital	1.10B

Metric
Revenue	1.20B
Revenue (LTM)
Revenue (NTM)
Gross Profit	974.22M
EBITDA	-343.52M
Operating Income	-452.26M
Net Income	-288.26M
EPS	-5.04
Diluted EPS	-5.04
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.91
Operating Profit Margin	-0.22
EBITDA Margin	-0.29
Net Profit Margin	-0.13
Return on Equity	-0.06
Return on Assets
Return on Capital Employed

COM:ARGENX

argenx

Last Close

582.60

25/11 09:24

Market Cap

25.12B

Beta: -

Volume Today

4.76K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-98.84
P/B Ratio	8.11
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	23.58
EV Multiple	-61.21

Metric
Days Sales Outstanding	130.26
Days Payables Outstanding	781.98
Days Inventory Outstanding	961.94
Operating Cycle	1.11K
Cash Conversion Cycle	349.92
Asset Turnover	0.44

Metric
Operating Cash Flow	-320.03M
Free Cash Flow	-362.84M
Cash Flow to Debt	13.04
Operating Cash Flow/Sales	0.15
Free Cash Flow Yield

Metric
Cash & Equivalents	1.96B
Accounts Receivable	-181.42M
Inventory	296.94M
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.00
Current Ratio	8.47
Quick Ratio	8.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.71
SG&A to Revenue